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                    Final Examination  
 
 
PHA411 – Therapeutics C 
DURATION 
 
Reading Time: 10 minutes 
Writing Time: 180 minutes 
 
INSTRUCTIONS TO CANDIDATES 
 
The examination has THREE (A, B and C) Sections: 
 
Section A:  Multiple Choice Questions: Answer ALL forty (40) questions on the College 100-MCQ Answer Sheet 
provided.  Total marks allocated: Forty (40).  Suggested allocated time: 60 minutes 
 
Section B:  Extended Answer Questions:  Answer any 4 out of 5 questions.  Marks as indicated by lecturer.  Total 
marks allocated: Forty (40).  Suggested allocated time:  60 minutes. 
 
Section C:  Case Study Questions:  Answer ALL (2) questions.  Total marks allocated: Forty (40).  Suggested 
allocated time:  60 minutes 
 
EXAM CONDITIONS 
You may begin writing from the commencement of the examination session.  The reading time indicated above is 
provided as a guide only. 
This is a CLOSED BOOK examination 
Any non-programmable calculator is permitted 
No handwritten notes are permitted 
No dictionaries are permitted 
 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
 




1 x 8 Page Book 
1 x 20 Page Book 
College Multiple Choice Answer Sheet 
 
 
Family Name  
Given Name/s  
Student Number       
Teaching Period Semester 1, 2018 
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Extended Answer Questions 
Total No of Marks for this section:  40 
 
This section should be answered in the Answer Booklet provided. 
Answer any FOUR (4) questions only. 
 






Caroline is a 32 year-old Aboriginal Liaison Officer at the local hospital. She has been trying to conceive 
for 16 months without any luck, and presents at the pharmacy requesting a treatment for vaginal 
thrush.  She tells you this is her third episode of thrush in the last 5 months.  She is hirsute and has a 
BMI of 31.5kg/m2.  You suspect she is displaying signs of polycystic ovarian syndrome (PCOS). 
 
(a) Explain her signs and symptoms and how these relate to PCOS. 
(Marks: 4) 
 
(b) Give TWO diagnostic criteria for PCOS. 
 (Marks: 2) 
 
(c) What treatment options are available to her, and what desired effect will these have on her 







a) Discuss the pathophysiology and clinical presentation of benign prostatic hyperplasia (BPH).  




b) Describe the mechanisms of action of TWO (2) different classes of therapeutic agents available 
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Eloise is a 48 year-old woman seeking some advice on “the change of life”.  For the past few weeks she 
has been experiencing hot flushes several times throughout the day, and is sleeping very poorly as a 
result of waking in a “pool of sweat”.  Elouise has had a levonorgestrel IUD in place for 2 years as a 
means of contraception, and the last time she had a period (“they normally only last 2 days since I’ve 
had the IUD”) was 6 months ago.  She is feeling quite emotional and teary and wants to know if she 
should be using hormone replacement therapy (HRT).  She has no history of cancer, is a non-smoker, 
takes Ramipril 5mg daily for blood pressure control and thyroxine for hypothyroidism. 
 
(a) Based on her history and symptoms, at what stage of menopause is Eloise?  Explain. 
(Marks: 3) 
 
(b) Is Eloise a candidate for HRT?  Explain why/why not and if so what hormonal formulations would 
be suitable, with an explanation for your choice. 
(Marks: 4) 
 
(c) Eloise wants to know if she can have her IUD removed if she starts HRT.  Comment on this and 








(a) Identify FOUR (4) risk factors for the development of lung cancer. 
(Marks: 2) 
 
(b) Name the TWO (2) broad categories of lung cancer and how their diagnosis is defined. 
(Marks: 2) 
 
(c) Compare and contrast these 2 categories of lung cancer, including the doubling time,  
      prognosis, staging and treatment options. 
(Marks: 4) 
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 A 45 year-old woman has been recently diagnosed with advanced ovarian cancer.  Following extensive 
staging and de-bulking surgery, she is due to commence her first cycle of carboplatin (IV) + paclitaxel 
(IV) (6 cycles at 21 day intervals).  In addition to her chemotherapy, she has been prescribed the 
following treatment protocol; 
 
Cycle 1 and further cycles 
Day before chemotherapy 
Dexamethasone 4mg tablets 20mg (oral) The night before chemo with 
or after food 





0.5mg/300mg (oral) 60 minutes before chemo 
Dexamethasone 4mg tablet 12mg (oral)  60 minutes before chemo 
Ranitidine 150mg tablet 150mg (oral) 60 minutes before chemo 
Loratadine 10mg tablet 10mg (oral) 60 minutes before chemo 
Day 2 to 4 
Dexamethasone 4mg tablet 8mg (oral) ONCE a day (or in divided 
doses) with or after food 
 
 
(a) Identify the TWO (2) indications for this range of drug therapies (additional to her   
      chemotherapy). 
 (Marks: 2) 
 
(b) Match the list of medications with these TWO (2) indications.  Include in your answer the  
      drug classes (e.g. β-blocker), why they are deemed to be of benefit to this patient and why  
      several medications are used to manage only two indications. 
(Marks: 6) 
 







End of Section B 
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Case Study Questions 
Total Number of Marks for this section: 40 
 
This section should be answered in the Answer Booklet provided. 
 
Marks for each question are indicated.  Suggested Time allocation for Section C:  60 mins 
 
 
Question 1 (20 marks) 
 
JD, a 53 year old man, presents to his general practitioner (GP) with lower back pain that has increased 
over the last month, and fatigue.  He has been using over-the-counter diclofenac for his back pain but 
with little benefit.  Further tests reveal a compression fracture in his lumbar spine, haemoglobin of 
85g/L (normal 130-180), platelets of 140 x 109/L (normal 150-400) serum calcium of 3.2 mmol/L (normal 
2.1 -2.6) and serum creatinine of 165µmol/L (normal 60-120).  Results from a 24 hour urinalysis show 
5.2g total protein with 77% Bence-Jones proteins.  A bone marrow biopsy confirms a diagnosis of 
multiple myeloma. 
 
(a) Briefly discuss the pathophysiology of multiple myeloma, including information that the bone 
             marrow biopsy would highlight. (hint: what cells does multiple myeloma manifest in?) 
  (Marks: 4) 
 
(b) The acronym CRAB is used to describe common presenting symptoms of multiple myeloma.   
                   What sign/symptom does each letter represent, and discuss if JD is exhibiting these? 
(Marks: 4) 
 
A decision is made to start JD on the induction regimen of thalidomide and dexamethasone as he is a 
potential candidate for autologous haematopoietic stem cell transplantation (HSCT). 
 
(c) Define HSCT and discuss the differences between autologous and allogeneic stem cell  
      transplantation. 
      (Marks: 3) 
 
(d) What is the purpose of using thalidomide and dexamethasone as induction therapy? 
(Marks: 3) 
 
(e) Suggest THREE (3) additional supportive therapies/agents (hint: to manage his presenting  
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Question 2 (20 marks) 
 
Mrs WD, a 63 year-old female of Asian heritage presented to the emergency department of her local 
hospital following a week of severe nausea and vomiting, abdominal pain and cramps.  She had 
attended an after-hours medical centre four days prior, and the general practitioner (GP) on duty had 
prescribed antibiotics, which had failed to resolve her symptoms. When her symptoms first began, WD 
also had several episodes of non-watery diarrhoea, but she had not been able to open her bowels (pass 
faeces) for 5 days since then.  
She appeared fatigued and in distress when she presented to the hospital for further examination.  She 
had a 7cm×10cm tender and palpable mass on the left upper quadrant (LUQ) of her abdomen and her 
imaging tests (X-ray and CT scan) results revealed a severe obstruction in her descending colon due to 
the presence of a solid mass with bowel wall invasion.  Hepatomegaly was also noted and her bowel 
sounds were very weak. 
Mrs WD’s other medical conditions included type 2 diabetes, mild hypertension, dyslipidaemia, 
osteoarthritis, suspected haemorrhoid (self-diagnosed) and anaemia which was noted approximately 4 
months ago by her regular GP. 
Mrs WD (165cm in height and 89kg in weight) had 2 children, both in their late 20s.  She smoked 
cigarettes briefly when she was in her early 30s but gave it up when she was pregnant with her first 
child.  She claimed to have lost 8kg over the past 12 months. 
Mrs WD’s medications on admission included: 
 
Atorvastatin 40mg tablet 1 daily 
Irbesartan 75mg tablet 1 daily 
Metformin XR 1000mg tablet 1 daily 
Gliclazide-MR 60mg tablet 2 daily  
Paracetamol 500mg tablet 2 twice daily when required 
Pantoprazole 40mg tablet 1 daily 
Docusate + sennosides tablet 1-2 night when required 
  
Mrs WD’s family medical histories included: 
 Father passed away from bowel cancer 20 years ago 
 Mother passed away from a heart attack 10 years ago 
 Older brother with diabetes 
 Maternal aunt breast cancer survivor 
 
Mrs WD underwent an emergency colon resection.  Several adenomatous polyps were found in the 
resected colon and the tissues taken from the area causing her bowel obstruction were identified as 
“carcinoma”. Mrs WD was subsequently diagnosed with Stage IIIC colon cancer. 
 
(a) What are the known risk factors for colorectal cancer?  Which of these risk factors are  
     applicable to Mrs WD? 
 (Marks: 4) 
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 (b) What screening tests are available for early detection of colorectal cancer?  From where  
                    could Mrs WD have accessed these?  
                        (Marks: 2) 
 
(c) Given that Mrs WD has been diagnosed with Stage IIIC colon cancer, what is the goal of  
      treatment, and why? 
(Marks: 2) 
                    
Adjuvant chemotherapy of FOLFOX (5-fluorouracil, leucovorin—also known as folinic acid, and 
oxaliplatin) was administered. Despite completing six cycles of adjuvant chemotherapy, Mrs WD’s 
disease progressed and a CT scan revealed metastases to her liver.  She was commenced on FOLFIRI   
(leucovorin, 5-fluorouracil and irinotecan) and underwent testing for K-RAS mutation in order to 
determine the suitability of a targeted therapy.  The results indicated WD was positive for K-RAS 
mutation. 
 
  (d) Describe the mechanisms of action of the THREE (3) chemotherapeutic agents used to  
                    treat Mrs WD’s metastatic colon cancer (FOLFIRI).  Include in your answer TWO (2) toxicities  
                    of each agent. 
(Marks: 6) 
 
 (e) Comment on the suitability of the targeted therapies, bevacizumab or cetuximab as    
       additional therapy to the chemotherapy for Mrs WD.  Include in your answer the target sites     
       for bevacizumab and cetuximab, and the mode of action of each of these agents. 
(Marks: 4) 
 
(f) If Mrs WD’s results indicated she was K-RAS wild type, would the suitability of bevacizumab  




                             
 







End of Exam Paper 
 
 
